Health Economics›Atypical hemolytic uremic syndrome›All lines of therapy

All lines of therapy

Atypical hemolytic uremic syndrome · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ravulizumab monotherapy Variant #01	—	R 59 910	14d	—	—	—	—	—
Eculizumab monotherapy N/A - secondary systemic drug	—	R 0	—	—	—	—	—	—

2 of 2 regimens shown